By Beau Phillips, Executive Director, US*MADE The pharmaceutical industry has long opposed the practice of inter partes review (IPR) at the U.S. Patent and Trademark
By Laura Bradford American manufacturers need the protection patents provide, but they don’t need bad actors trying to extort money from them by filing bogus
Washington, DC –November 30, 2021 – Outlining how she will protect America’s position as an innovation leader and preserve manufacturing growth in the U.S. should
Biden’s USPTO Pick Can Restore Much-Needed Patent Reform – Law360 In nominating Kathi Vidal as new director of the U.S. Patent and Trademark Office, President
By TROY R. LESTER | August 7, 2021 at 4:39 p.m. Bad, overly broad patents are harmful to U.S. manufacturing companies and are antithetical to their intended purpose of